- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01757665
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE) (COMMENCE)
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform (COMMENCE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 4G5
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec
-
-
-
-
-
Krakow, Poland, 31-202
- Krakowski Szpital Specjalistyczny im. Jana Pawla II
-
Warsaw, Poland, 04-628
- The Cardinal Stefan Wyszynski Institute of Cardiology
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35211
- Cardiology, P.C.
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Sacramento, California, United States, 95919
- Sutter Institute for Medical Research
-
Stanford, California, United States, 94305
- Board of Trustees of the Leland Stanford Junior University
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale-New Haven
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Shands at the University of Florida
-
Orlando, Florida, United States, 32803
- Florida Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Hospital Midtown
-
-
Indiana
-
Indianapolis, Indiana, United States, 46290
- St. Vincent Heart Center of Indiana
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Baltimore
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health Hospital
-
-
Mississippi
-
Tupelo, Mississippi, United States, 38801
- North Mississippi Medical Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 36131
- Missouri Baptist Medical Center
-
Saint Louis, Missouri, United States, 63110
- Washington University/ Barnes Jewish Hospital
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, United States, 10032
- New York Presbyterian Hospital - Columbia University Medical Center
-
New York, New York, United States, 10025
- Mount Sinai Morningside
-
New York, New York, United States, 10021
- New York Weill Cornell Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center
-
Columbus, Ohio, United States, 43124
- OhioHealth Research Institute
-
-
Pennsylvania
-
Mechanicsburg, Pennsylvania, United States, 17050
- Pinnacle Health Cardiovascular Institute
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- St. Thomas Health
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
Houston, Texas, United States, 77030
- Michael E. DeBakey VA Medical Center
-
Plano, Texas, United States, 75093
- The Heart Hospital of Baylor Plano
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Eligibility Criteria:
Inclusion Criteria:
- Is 18 years or older
- Provides written informed consent prior to trial procedures
- Agrees to attend all follow-up assessments for up to 5 years and is willing to comply with specified follow-up evaluations at clinical investigational sites that are participating in the COMMENCE trial and/or obtain the protocol-specified diagnostic tests at centers that are under the same IRB or the same healthcare system
- Diagnosed with aortic or mitral valve disease requiring valve replacement based on pre- operative evaluation
- Scheduled to undergo planned aortic or mitral valve replacement with or without concomitant bypass surgery
- Scheduled to undergo planned aortic valve replacement with or without resection and replacement of the ascending aorta from the sinotubular junction and without the need for circulatory arrest for hemi arch or arch replacement
Exclusion criteria:
A subject meeting any of the following criteria shall be excluded:
- Requires emergency surgery
- Requires planned multiple valve replacement/ repair (with the exception of mitral valve replacement with tricuspid valve repair)
- Has prior valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ
- Requires a surgical procedure outside of the cardiac area (e.g. vascular bypass)
- Requires surgical replacement of the aortic root
- Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months to the scheduled aortic or mitral valve replacement surgery
- Has renal insufficiency as determined by creatinine (S-Cr) level ≥ 2.5 mg/dL or end -stage renal disease requiring chronic dialysis at screening visit
- Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months (180 days) prior to planned valve surgery
- Has acute myocardial infarction (MI) within 30 days prior to planned valve surgery
- Has presence of non-cardiac disease limiting life expectancy to less than 12 months
- Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM)
- Diagnosed with abnormal calcium metabolism and hyperparathyroidism
- Exhibits left ventricular ejection fraction ≤ 20% as validated by diagnostic procedure prior to planned valve surgery
- Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation
- Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery
- Documented leukopenia (WBC < 3.5x 10³/μL), acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L) or thrombocytopenia (platelet count < 50x 10³/μL) accompanied by history of bleeding diathesis and coagulopathy
- Has prior organ transplant or is currently an organ transplant candidate
- Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
- Was previously implanted with trial device (Model 11000A or Model 11000M)
- Pregnant (female subject of childbearing potential only), lactating or planning to become pregnant during the duration of participation in trial
- Currently incarcerated or unable to give voluntary informed consent
- Documented history of substance (drug or alcohol) abuse within the last 5 years prior to implant
- Requires concomitant left ventricular assist device (LVAD) placement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M
Aortic/Mitral valve replacement therapy
|
Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects With Structural Valve Deterioration
Time Frame: 1 Year Post Implant
|
The rate of implanted subjects that experience structural valve deterioration (SVD) of the trial valve by the time of the post operative day (POD) 390 follow-up visit.
Structural valve deterioration includes dysfunction or deterioration intrinsic to the valve.
Examples of SVD includes complications such as wear, fracture, calcification, leaflet tear.
|
1 Year Post Implant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Early Adverse Events
Time Frame: Events occuring within 30 days of procedure
|
Number of subjects with early adverse events occurring within 30 days of procedure divided by the number of enrolled subjects times 100
|
Events occuring within 30 days of procedure
|
Percentage of Late Adverse Events Divided by Late Patient Years
Time Frame: Events occurring >= 31 days and up through 3 years post-implant
|
Number of late events divided by the total number of late patient years times 100.
Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).
|
Events occurring >= 31 days and up through 3 years post-implant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject's Average Mean Gradient Measurements - 11000A
Time Frame: 3 Months, 1 Year, and 2 Year Post Implant
|
Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Gradients are evaluated by echocardiography over time.
Mean gradient values depend on the size and type of valve.
|
3 Months, 1 Year, and 2 Year Post Implant
|
Subject's Average Mean Gradient Measurements - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Mean gradient is the average flow of blood through the mitral valve measured in millimeters of mercury.
Gradients are evaluated by echocardiography over time.
Mean gradient values depend on the size and type of valve.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Peak Gradients Measurements Over Time - 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Gradients are evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Peak Gradients Measurements Over Time - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Peak gradient is the maximum value measured of flow of blood through the mitral valve as measured in millimeters of mercury.
Gradients are evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Effective Orifice Area Measurements - 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve.
Effective orifice area is evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Effective Orifice Area Measurements - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Effective orifice area represents the cross-sectional area of the blood flow downstream of the mitral valve.
Effective orifice area is evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area.
Effective orifice area index is evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the mitral valve divided by the person's body surface area.
Effective orifice area index is evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Performance Index Measurements - 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Performance index is defined as the subject's effective orifice area (the cross sectional area of the blood flow downstream of the aortic valve) divided by the subject's native orifice area.
Effective orifice area is evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Performance Index Measurements - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Performance index is defined as the subject's effective orifice area (the crosssectional area of the blood flow downstream of the mitral valve) divided by the subject's native orifice area.
Effective orifice area is evaluated by echocardiography over time.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Cardiac Output Over Time - 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
The amount of blood the heart pumps through the circulatory system in a minute.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Cardiac Output Over Time - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
The amount of blood the heart pumps through the circulatory system in a minute.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Cardiac Index Over Time- 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area (BSA), thus relating heart performance to the size of the individual.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Cardiac Index Over Time - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area(BSA), thus relating heart performance to the size of the individual.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Amount of Total Valvular Regurgitation Over Time - 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it.
Valvular regurgitation is evaluated by echocardiography over time.
It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Amount of Total Valvular Regurgitation Over Time - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Mitral valvular regurgitation occurs when the mitral valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it.
Mitral valvular regurgitation is evaluated by echocardiography over time.
It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.
|
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Amount of Paravalvular Leak Over Time - 11000A
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome. |
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Amount of Paravalvular Leak Over Time - 11000M
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome. |
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline
Time Frame: 3 Months, 1 Year, and 2 Years Post Implant
|
The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases. |
3 Months, 1 Year, and 2 Years Post Implant
|
Subject's Average Score at Baseline and 1 Year on the Quality of Life Survey
Time Frame: Baseline and one year post-implant
|
The Medical Outcomes Study Short-Form 12 (SF-12) contains two components - the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The SF-12 Physical Component Summary questionnaire scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status. The SF-12 Mental Component Summary scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status. |
Baseline and one year post-implant
|
Subject's Average White Blood Cell Count
Time Frame: Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection.
|
Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Subject's Average Red Blood Cells Count
Time Frame: Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Laboratory Analysis of Red Blood Cell (RBC) Count on blood drawn from subjects; RBC carry oxygen.
|
Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Subject's Average Hematocrit Percentage
Time Frame: Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects.
Hematocrit is the proportion of red blood cells to the plasma (liquid portion of the blood).
|
Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Subject's Average Hemoglobin Count
Time Frame: Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Laboratory Analysis of Hemoglobin Count on blood drawn from subjects.
Hemoglobin is an oxygen-carrying protein in red blood cells.
|
Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Subject's Average Platelet Count
Time Frame: Baseline, Discharge, 3 Months, 1 Year, and 2 Years
|
Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.
|
Baseline, Discharge, 3 Months, 1 Year, and 2 Years
|
Subject's Average Plasma Free Hemoglobin
Time Frame: Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Laboratory Analysis of Plasma Free Hemoglobin on blood drawn from subjects.
This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood).
|
Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Subject's Average International Normalized Ratio
Time Frame: Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Laboratory Analysis of International Normalized Ratio (INR) on blood drawn from subjects.
The INR is a calculation based on results of a prothrombin time (PT).
The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot.
INR results will vary according to a person's age, the medicines they take, and any health problems they may have.
In general, the higher the INR number, the longer it takes for the blood to clot.
In healthy people an INR of 1.1 or below is considered normal.
An INR range of 2.0 to 3.0 is generally an effective therapeutic range for people taking blood thinner medication.
|
Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Subject's Average Partial Thromboplastin Time
Time Frame: Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Laboratory Analysis of partial thromboplastin time (PTT) on blood drawn from subjects.
PTT is a blood test that looks at how long it takes for the blood to clot.
|
Baseline, Discharge, 3 Months, 1 Year and 2 Year
|
Subject's Average Prothrombin Time
Time Frame: Baseline, Discharge, 3 Months, 1 Year, and 2 Years
|
Laboratory Analysis of Prothrombin Time (PT) on blood drawn from subjects.
The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot.
|
Baseline, Discharge, 3 Months, 1 Year, and 2 Years
|
Subjects Average Serum Glycerol Levels
Time Frame: Pre-Implant (post-heparinization) and Post-Implant (between 60 and 120 minutes after heart was restarted)
|
Laboratory analysis of serum glycerol in blood drawn from subjects.
This blood test measures the amount of glycerol (a naturally occurring carbohydrate, that can be used as a fuel source by the body) in the serum (liquid portion of the blood).
|
Pre-Implant (post-heparinization) and Post-Implant (between 60 and 120 minutes after heart was restarted)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Puskas, MD, Icahn School of Medicine at Mount Sinai
Publications and helpful links
General Publications
- Puskas JD, Bavaria JE, Svensson LG, Blackstone EH, Griffith B, Gammie JS, Heimansohn DA, Sadowski J, Bartus K, Johnston DR, Rozanski J, Rosengart T, Girardi LN, Klodell CT, Mumtaz MA, Takayama H, Halkos M, Starnes V, Boateng P, Timek TA, Ryan W, Omer S, Smith CR; COMMENCE Trial Investigators. The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue. Eur J Cardiothorac Surg. 2017 Sep 1;52(3):432-439. doi: 10.1093/ejcts/ezx158.
- Johnston DR, Griffith BP, Puskas JD, Bavaria JE, Svensson LG; COMMENCE Trial Investigators. Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue. J Thorac Cardiovasc Surg. 2021 Nov;162(5):1478-1485. doi: 10.1016/j.jtcvs.2020.01.095. Epub 2020 Feb 21.
- Bavaria JE, Griffith B, Heimansohn DA, Rozanski J, Johnston DR, Bartus K, Girardi LN, Beaver T, Takayama H, Mumtaz MA, Rosengart TK, Starnes V, Timek TA, Boateng P, Ryan W, Cornwell LD, Blackstone EH, Borger MA, Pibarot P, Thourani VH, Svensson LG, Puskas JD; COMMENCE Trial Investigators. Five-year Outcomes of the COMMENCE Trial Investigating Aortic Valve Replacement With RESILIA Tissue. Ann Thorac Surg. 2023 Jun;115(6):1429-1436. doi: 10.1016/j.athoracsur.2021.12.058. Epub 2022 Jan 20.
- Heimansohn DA, Baker C, Rodriguez E, Takayama H, Dagenais F, Talton DS, Mumtaz MA, Pibarot P, Puskas JD; COMMENCE Trial Investigators. Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue. JTCVS Open. 2023 Jun 2;15:151-163. doi: 10.1016/j.xjon.2023.05.008. eCollection 2023 Sep.
- Beaver T, Bavaria JE, Griffith B, Svensson LG, Pibarot P, Borger MA, Sharaf OM, Heimansohn DA, Thourani VH, Blackstone EH, Puskas JD; COMMENCE Trial Investigators. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2023 Sep 29:S0022-5223(23)00873-5. doi: 10.1016/j.jtcvs.2023.09.047. Online ahead of print.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-02 (AP HM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M
-
Tau Pnu Medical Co., Ltd.CompletedHeart Failure | Atrial Functional Mitral RegurgitationKorea, Republic of
-
Tau Pnu Medical Co., Ltd.CompletedHeart Failure | Functional Mitral RegurgitationUnited States, Korea, Republic of
-
Edwards LifesciencesCompletedCritical Aortic StenosisUnited States, Canada, Germany
-
Medical University of BialystokCompletedCoronary Artery Disease | Chronic Kidney Diseases | Aortic Valve Stenosis | Valvular Heart Disease | Mitral Stenosis | Valvular Disease | Mitral Insufficiency and Aortic StenosisPoland
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...CompletedSurgery | Hepatic Impairment | Cardiac Disease | Hyperbilirubinemia
-
University College, LondonSociety for Cardiothoracic Surgery in Great Britain & Ireland; British Congenital...Unknown